Please assess the completion status of the following clinical trial:

Trial Title: REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy child without chronic severe disease of either gender,~2. 6 year-old child on vaccination day,~3. Child previously vaccinated with three doses of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination within the first 6 months of life and a booster dose of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination at 16 - 18 months of life (±2 months),~4. Consent form signed by both parents, or by the legal representative, properly informed about the study.~Exclusion Criteria:~1. Child who had received less or more than 4 doses of a diphtheria, tetanus and/or poliomyelitis containing vaccine,~2. Previous clinical or bacteriological diagnosis of diphtheria, tetanus or poliomyelitis,~3. Child who had received any vaccine in the previous 30 days or with a vaccination scheduled during the course of the study,~4. Child who present with immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity,~5. Child who had received within the previous 150 days or who will receive during the course of the study, any immunoglobulins or blood derived products,~6. Child with true hypersensitivity to at least one of the components of a study vaccine or to streptomycin, neomycin or polymixin B,~7. Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition,~8. Child who had presented severe hypersensitivity following an earlier immunization against diphtheria and/or tetanus,~9. Known history of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection,~10. Acute severe febrile illness and/or oral temperature ≥37.5°C at the time of vaccination

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).